Evidence map›Paper›PMID 34636027›Full record

ArticleTurk patoloji dergisi2022

Invasive Breast Carcinoma of No Special Type with Medullary Pattern: Morphological and Immunohistochemical Features.

Mykola Lуndіn, Nataliia Hyriavenko, Vladyslav Sikora, Yuliia Lуndіna, Yuliia Soroka, Anatolii Romaniuk

Open access · diamondAbstract read
In one paragraph

Article in Turk patoloji dergisi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mykola LуndіnDepartment of Pathology, Medical Institute, Sumy State University, SUMY, UKRAINE.
Nataliia Hyriavenko
Vladyslav Sikora
Yuliia Lуndіna
Yuliia Soroka
Anatolii Romaniuk
Sumy State University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOur study investigated the morphological and immunohistochemical characteristics of invasive breast carcinoma of no special type (IBC-NST) with medullary pattern to explore the inconsistencies between the structural and clinical traits of this category of tumor. MATERIAL AND

methodThe breast carcinoma samples (n = 26) with medullary pattern (defined according to established criteria) were subjected to immunohistochemical assays of the following receptors: ER, PR, HER2/neu, Ki-67, p53, Bcl-2, VEGF, MMP1, E-cadherin, EGFR, Hsp70, Hsp90, CD20, CD3, CD4, CD8, CD68, CD163, CD56, CD138, MPO, S100, IgG, IgM, and PD-L1.

resultsIBC-NST with medullary pattern was found to have negative expression of ER, PR, and HER2/neu; strong positive expression of Kі-67, mutant р53, Bcl-2, E-cadherin, EGFR, and PD-L1; moderate positive expression of Hsp70 and Hsp90; and low or negative expression of VEGF and MMP1. Furthermore, there was pronounced variability in the qualitative composition of tumor immune infiltrates with regards to T-lymphocytes, B-lymphocytes, macrophages, plasmocytes, and granulocytes.

conclusionIBC-NST with medullary pattern has many unfavourable morphological and immunohistochemical prognostic characteristics, which are balanced against the pronounced protective properties of the tumor cells and the qualitative characteristics of the tumor microenvironment. These can lead to a favourable disease course despite the relatively adverse features of the carcinoma cells.

Indexed as

B7-H1 AntigenBreast NeoplasmsBiomarkers, TumorCadherinsErb-b2 Receptor Tyrosine KinasesFemaleHumansKi-67 AntigenMatrix Metalloproteinase 1PrognosisProto-Oncogene Proteins c-bcl-2Tumor MicroenvironmentVascular Endothelial Growth Factor AB7-H1 AntigenBiomarkers, TumorCadherinsErb-b2 Receptor Tyrosine KinasesKi-67 AntigenMatrix Metalloproteinase 1Proto-Oncogene Proteins c-bcl-2Vascular Endothelial Growth Factor A

Identifiers

PMID34636027
PMCPMC10508404
OpenAlexW3205279914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.